Covishield Safety Concerns Prompt Doctors’ Group to Call for Comprehensive Review of All Covid Vaccines
PTK Exclusive Report
New Delhi : In light of AstraZeneca’s recent acknowledgment of rare blood clotting side effects associated with its COVID-19 vaccine, concerns over the safety of Covishield, produced by the Serum Institute of India, have intensified.
Under the banner of the Awaken India Movement (AIM), a group of doctors convened a press conference urging the government to conduct a comprehensive review of all COVID-19 vaccines. Dr. Tarun Kothari, a prominent radiologist and activist, emphasized the need for scientific scrutiny and epidemiological investigation into vaccine safety.
Dr. Sujata Mittal, a gynecologist and oncologist, highlighted the lack of complete data on potential side effects and fatalities during the initial rollout of COVID-19 vaccines. She stressed the importance of early identification of adverse events and the implementation of effective monitoring mechanisms.
The AIM has been advocating for greater transparency and accountability regarding vaccine-related deaths and injuries since the onset of vaccination campaigns. Dr. Kothari emphasized the government’s responsibility to compensate victims and their families and called for the establishment of specialized courts to expedite legal proceedings.
With AstraZeneca announcing the global withdrawal of its COVID-19 vaccine, marketed as Covishield in India, concerns have heightened. The company cited surplus vaccine availability and rare side effects as reasons for the withdrawal. However, the Serum Institute of India maintains that it had disclosed all known side effects, including Thrombosis with Thrombocytopenia Syndrome (TTS), in its packaging inserts.
As debates over vaccine safety continue, calls for transparent evaluation and stringent monitoring mechanisms grow louder, underscoring the urgent need to safeguard public health amidspandemic.9oing pandemic.
